Cardiac Hemangioma

Inquiry

Cardiac Hemangioma

Cardiac hemangioma accounts for approximately 2.8% of primary cardiac tumors. This is a condition that arises in the pericardium, myocardium, or endocardium. Protheragen is a total solution provider in the research and development of therapeutics for rare heart diseases. We use innovative technology and a comprehensive scientific strategy to advance the discovery and development of therapeutics for cardiac hemangioma.

Introduction to Cardiac Hemangioma

Hemangioma is an uncommon benign cardiac tumor, and presents as a sporadic, isolated finding at a mean age of the 5th decade. Pathologically, hemangiomas are found to be made up of benign proliferating endothelial cells located in the vessel walls, which become increasingly vascular. Microscopically, the vascular spaces of hemangioma are lined by endothelial cells with moderate pleomorphism and sometimes atypical nuclei and focal tufts. Mitoses are extremely rare. Electron microscopy reveals interdigitation of the endothelial cells and a lack of desmosomes or tight junctions. According to the principal type of the proliferating vessels, hemangiomas are categorized into cavernous, arteriovenous, and capillary types.

Pathologic findings of left atrial cardiac hemangioma.Fig.1 Pathology of left atrial cardiac hemangioma. (Berdica, L., et al., 2023)

Pathogenesis of Cardiac Hemangioma

The exact mechanism is poorly understood but thought to be in part contributed to by abnormal reproduction of endothelial cells and generation of new blood vessels (angiogenesis). It is believed to be the result of a complex interplay of genetic influences, which results in defects of the complex cascade of signaling pathways involved in vasculogenesis. Moreover, inflammatory factors or local hemodynamic stress may also play a role in their enlargement.

Therapeutics Development for Cardiac Hemangioma

Drug Name Mechanism of Action Targets Research Phase
Corticosteroid Vasoconstriction and anti-inflammatory effects. It may reduce tumor size and inhibit endothelial cell proliferation. Glucocorticoid receptors Approved
Captopril modulating the renin-angiotensin system, which has been implicated in hemangioma biology. Angiotensin-converting enzyme (ACE) Approved
Propranolol A non-selective beta-blocker that induces apoptosis of endothelial cells and angiogenesis inhibition. Beta-1 and Beta-2 adrenergic receptors Approved

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a therapy plan recommendation. For guidance on therapy options, please visit a regular hospital.

Our Services

From advanced diagnostics to novel therapeutic development, Protheragen has the competencies to realize the full potential of a comprehensive strategy for heart hemangioma. Our services cover the entire chain from advanced disease models and rigorous preclinical studies to further studies of promising drugs. These critical steps enable us to make a deep investigation of the complex process in the growth of cardiac hemangioma, to search for potential drugs, test their therapeutic effects, and assess their safety in controlled conditions.

Therapeutic Development Services

Animal Model Development for Cardiac Hemangioma

Animal models are critical links in the cardiac hemangioma of drug screening and development. We understand the unmet needs faced by rare diseases such as cardiac hemangioma, and that is why we concentrate on offering tailored animal model development services for you, to help you on your way to breakthrough therapies for cardiac hemangioma.

Induced Animal Model

This approach involves administering chemical agents that are capable of either inducing neovascularization or possessing carcinogenic attributes to laboratory animals.

Optional models: Captafol-induced model, other models.

Pharmacokinetics and Drug Safety Research Services


In addition to the early discovery phase and preclinical validation, Protheragen expands its offerings to essential pharmacokinetic and drug safety studies. Pharmacokinetic knowledge is the key to individualizing dose and minimizing toxicity, including knowledge of how a drug is absorbed, distributed, metabolized, and excreted in the body. Through providing this full service, we help our partners navigate the complexities of rare disease drug development. If you are interested in our services, please contact us.

Reference

  • Berdica, Leart et al. "Cardiac hemangioma presenting as a primary cardiac tumor." Cardio-oncology (London, England) 9.1 (2023): 3.

For research use only, not for clinical use.